A5 Labs Submits Provisional Patent Application to the United States Patent Office for the Production of Interferon-Based Products

MONTREAL, QUEBEC--(Marketwire - July 28, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced that the company has submitted a provisional patent application to protect its technology for the production of interferon-based products. In general the patent application describes the company’s new method for producing therapeutic proteins as well as specifically providing details of the production of company’s lead product VI-1718. A5 Lab’s lead product VI-1718 has potential broad based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections.

Dr. Richard Azani, President and CEO of A5 said, “The submission of this patent application is a very significant milestone in the development of our interferon-based products. I am very proud of our research team for their tireless work in completing the scientific and technological basis for this patent. We are now ready to advance the company’s plans towards production and commercialization of these products.”

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5’s products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5’s expansion efforts, economic conditions in the industry and the financial strength of A5’s customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.